MoonLake Immunotherapeutics (MLTX) FinancialsMLTXMoonLake Immunotherapeutics

Evaluating the bottom line, MoonLake Immunotherapeutics maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.44%, provide a clear picture of how effectively MLTX converts its operational activities into shareholder value.

In the context of the broader market, MLTX competes directly with industry leaders such as MNKD and SPTX. With a market capitalization of $1.32B, it holds a leading position in the sector. When comparing efficiency, MLTX's gross margin of N/A stands against MNKD's 69.00% and SPTX's N/A. Such benchmarking helps identify whether MoonLake Immunotherapeutics is trading at a premium or discount relative to its financial performance.

MoonLake reported a Q2 loss of $0.84 per share, which was better than the expected loss of $0.93, indicating improved financial management. However, the company has consistently reported losses, with a net income of -69,707,000 in Q1 2026 and -61,805,000 projected for Q2 2026.